Inhibition of nicotinamide phosphoribosyltransferase (NAMPT), an enzyme essential for NAD+ biosynthesis, leads to altered carbohydrate metabolism in cancer cells

Journal of Biological Chemistry

Volumn 290, Issue 25, 2015, Pages 15812-15824

  Tan, Bo ^a   Dong, Sucai ^a   Shepard, Robert L ^a   Kays, Lisa ^a   Roth, Kenneth D ^a   Geeganage, Sandaruwan ^a   Kuo, Ming Shang ^a   Zhao, Genshi ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDES; BIOCHEMISTRY; BIOSYNTHESIS; CARBOHYDRATES; CELLS; CYTOLOGY; DISEASES; ENZYMES; FRUCTOSE; GLUCOSE; METABOLISM; PATHOLOGY; PHYSIOLOGY;

BIOCHEMICAL STUDIES; CARBOHYDRATE METABOLISM; CELLULAR METABOLISM; DIHYDROXYACETONE PHOSPHATE; FRUCTOSE 1 ,6-BISPHOSPHATE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PHARMACOLOGICAL INHIBITION; TECHNICAL LIMITATIONS;

ENZYME INHIBITION;

ADENOSINE DIPHOSPHATE RIBOSYL CYCLASE; DAPORINAD; DIHYDROXYACETONE PHOSPHATE; FRUCTOSE 1 PHOSPHATE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; ACRYLAMIDE DERIVATIVE; CYTOKINE; ENZYME INHIBITOR; N-(4-(1-BENZOYLPIPERIDIN-4-YL)BUTYL)-3-(PYRIDIN-3-YL)ACRYLAMIDE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE, HUMAN; PIPERIDINE DERIVATIVE; SUGAR PHOSPHATE; TUMOR PROTEIN;

ARTICLE; CANCER CELL; CARBOHYDRATE METABOLISM; CONTROLLED STUDY; ENZYME INHIBITION; GLYCOLYSIS; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN SYNTHESIS; ANTAGONISTS AND INHIBITORS; GENETICS; METABOLISM; NEOPLASM; PATHOLOGY;

ACRYLAMIDES; CARBOHYDRATE METABOLISM; CYTOKINES; ENZYME INHIBITORS; HUMANS; MASS SPECTROMETRY; NAD; NEOPLASM PROTEINS; NEOPLASMS; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PIPERIDINES; SUGAR PHOSPHATES;

EID: 84940055387     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M114.632141     Document Type: Article

References (39)

1. + biosynthesis, in human cancer cells: metabolic basis and potential clinical implications. J. Biol. Chem. 288, 3500-3511
2. + biology, metabolism and cancer. Trends Endocrinol. Metab. 20, 130-138
3. Kirkland, J. B. (2009) Niacin status, NAD distribution and ADP-ribose metabolism. Curr. Pharm. Des. 15, 3-11
4. + homeostasis in man. Cell Mol. Life Sci. 61, 19-34
5. + and vitamin B3: from metabolism to therapies. J. Pharmacol. Exp. Ther. 324, 883-893
6. Olesen, U. H., Thougaard, A. V., Jensen, P. B., and Sehested, M. (2010) A preclinical study on the rescue of normal tissue by nicotinic acid in highdose treatment with APO866, a specific nicotinamide phosphoribosyltransferase inhibitor. Mol. Cancer Ther. 9, 1609-1617
7. Olesen, U. H., Christensen, M. K., Björkling, F., Jäättelä, M., Jensen, P. B., Sehested, M., and Nielsen, S. J. (2008) Anticancer agent CHS-828 inhibits cellular synthesis of NAD. Biochem. Biophys. Res. Commun. 367, 799-804
8. + biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors. Mol. Cell. Biol. 29, 5872-5888
9. Revollo, J. R., Grimm, A. A., and Imai, S. (2004) The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J. Biol. Chem. 279, 50754-50763
10. Rongvaux, A., Galli, M., Denanglaire, S., Van Gool, F., Drèze, P. L., Szpirer, C., Bureau, F., Andris, F., and Leo, O. (2008) Nicotinamide phosphoribosyl transferase/pre-B cell colony-enhancing factor/visfatin is required for lymphocyte development and cellular resistance to genotoxic stress. J. Immunol. 181, 4685-4695
11. Imai, S. (2009) Nicotinamide phosphoribosyltransferase (NAMPT): A link between NAD biology, metabolism, and diseases. Curr. Pharm. Des. 15, 20-28
12. Khan, J. A., Forouhar, F., Tao, X., and Tong, L. (2007) Nicotinamide adenine dinucleotide metabolism as an attractive target for drug discovery. Expert Opin. Ther. Targets 11, 695-705
13. Luk, T., Malam, Z., and Marshall, J. C. (2008) Pre-B cell colony-enhancing factor (PBEF)/visfatin: a novel mediator of innate immunity. J. Leukoc. Biol. 83, 804-816
14. Bi, T. Q., Che, X. M., Liao, X. H., Zhang, D. J., Long, H. L., Li, H. J., and Zhao, W. (2011) Overexpression of Nampt in gastric cancer and chemo-potentiating effects of the Nampt inhibitor FK866 in combination with fluorouracil. Oncol. Rep. 26, 1251-1257
15. Hufton, S. E., Moerkerk, P. T., Brandwijk, R., de Bruïne, A. P., Arends, J. W., Hoogenboom, H. R. (1999) A profile of differentially expressed genes in primary colorectal cancer using suppression subtractive hybridization. FEBS Lett. 463, 77-82
16. Van Beijnum, J. R., Moerkerk, P. T., Gerbers, A. J., De Bruïne, A. P., Arends, J. W., and Hoogenboom, H. R., and Hufton, S. E. (2002) Target validation for genomics using peptide-specific phage antibodies: a study of five gene products overexpressed in colorectal cancer. Int. J. Cancer 101, 118-127
17. Wang, B., Hasan, M. K., Alvarado, E., Yuan, H., Wu, H., and Chen, W. Y. (2011) NAMPT overexpression in prostate cancer and its contribution to tumor cell survival and stress response. Oncogene 30, 907-921
18. Nakajima, T. E., Yamada, Y., Hamano, T., Furuta, K., Gotoda, T., Katai, H., Kato, K., Hamaguchi, T., and Shimada, Y. (2009) Adipocytokine levels in gastric cancer patients: resistin and visfatin as biomarkers of gastric cancer. J. Gastroenterol. 44, 685-690
19. Busso, N., Karababa, M., Nobile, M., Rolaz, A., Van Gool, F., Galli, M., Leo, O., So, A., and De Smedt, T. (2008) Pharmacological inhibition of nicotinamide phosphoribosyltransferase/visfatin enzymatic activity identifies a new inflammatory pathway linked to NAD. PLoS One 3, e2267
20. Hasmann, M., and Schemainda, I. (2003) FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res. 63, 7436-7442
21. + levels dictate cell survival. Cell 130, 1095-1107
22. Drevs, J., Löser, R., Rattel, B., and Esser, N. (2003) Antiangiogenic potency of FK866/K22.175, a new inhibitor of intracellular NAD biosynthesis, in murine renal cell carcinoma. Anticancer Res. 23, 4853-4858
23. 31P magnetic resonance spectroscopy. Clin. Cancer Res. 11, 3503-3513
24. Giannetti, A. M., Zheng, X., Skelton, N. J., Wang, W., Bravo, B. J., Bair, K. W., Baumeister, T., Cheng, E., Crocker, L., Feng, Y., Gunzner-Toste, J., Ho, Y. C., Hua, R., Liederer, B. M., Liu, Y., Ma, X., O'Brien, T., Oeh, J., Sampath, D., Shen, Y., Wang, C., Wang, L., Wu, H., Xiao, Y., Yuen, P. W., Zak, M., Zhao, G., Zhao, Q., and Dragovich, P. S. (2014) Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropane-carboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT). J. Med. Chem. 57, 770-792
25. Zheng, X., Bauer, P., Baumeister, T., Buckmelter, A. J., Caligiuri, M., Clodfelter, K. H., Han, B., Ho, Y. C., Kley, N., Lin, J., Reynolds, D. J., Sharma, G., Smith, C. C., Wang, Z., Dragovich, P. S., Gunzner-Toste, J., Liederer, B. M., Ly, J., O'Brien, T., Oh, A., Wang, L., Wang, W., Xiao, Y., Zak, M., Zhao, G., Yuen, P. W., and Bair, K. W. (2013) Structure-based discovery of novel amide-containing nicotinamide phosphoribosyltransferase (nampt) inhibitors. J. Med. Chem. 56, 6413-6433
26. + depletion and cell death induced by oxidative stress. J. Biol. Chem. 278, 18426-18433
27. + depletion and reduced Sir2α deacetylase activity. J. Biol. Chem. 280, 43121-43130
28. Yu, S. W., Wang, H., Poitras, M. F., Coombs, C., Bowers, W. J., Federoff, H. J., Poirier, G. G., Dawson, T. M., and Dawson, V. L. (2002) Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science 297, 259-263
29. Clasquin, M. F., Melamud, E., Singer, A., Gooding, J. R., Xu, X., Dong, A., Cui, H., Campagna, S. R., Savchenko, A., Yakunin, A. F., Rabinowitz, J. D., and Caudy, A. A. (2011) Riboneogenesis in yeast. Cell 145, 969-980
30. Rellos, P., Sygusch, J., and Cox, T M. (2000) Expression, purification, and characterization of natural mutants of human aldolase B: role of quaternary structure in catalysis. J. Biol. Chem. 275, 1145-1151
31. Kitajima, Y., Takasaki, Y., Takahashi, I., and Hori, K. (1990) Construction and properties of active chimeric enzymes between human aldolases A and B: analysis of molecular regions which determine isozyme-specific functions. J. Biol. Chem. 265, 17493-17498
32. Kusakabe, T., Motoki, K., and Hori, K. (1994) Human aldolase C: characterization of the recombinant enzyme expressed in E. coli. J. Biochem. 115, 1172-1177
33. Bais, R., James, H. M., Rofe, A. M., and Conyers, R. A. (1985) The purification and properties of human liver ketohexokinase: a role for ketohexokinase and fructose-bisphosphate aldolase in the metabolic production of oxalate from xylitol. Biochem. J. 230, 53-60
34. Kardon, T., Stroobant, V., Veiga-da-Cunha, M., and Schaftingen, E. V. (2008) Characterization of mammalian sedoheptulokinase and mechanism of formation of erythritol in sedoheptulokinase deficiency. FEBS Lett. 582, 3330-3334
35. Hwa, J. S., Kim, H. J., Goo, B. M., Park, H. J., Kim, C. W., Chung, K. H., Park, H. C., Chang, S. H., Kim, Y. W., Kim, D. R., Cho, G. J., Choi, W. S., Kang, K. R. (2006) The expression of ketohexokinase is diminished in human clear cell type of renal cell carcinoma. Proteomics 6, 1077-1084
36. Albery, W. J., and Knowles, J. R. (1976) Evolution of enzyme function and the development of catalytic efficiency. Biochemistry 15, 5631-5640
37. Wierenga, R. K., Kapetaniou, E. G., and Venkatesan, R. (2010) Triosephosphate isomerase: a highly evolved biocatalyst. Cell Mol. Life Sci. 67, 3961-3982
38. Catchpole, G., Platzer, A., Weikert, C., Kempkensteffen, C., Johannsen, M., Krause, H., Jung, K., Miller, K., Willmitzer, L., Selbig, J., and Weikert, S. (2011) Metabolic profiling reveals key metabolic features of renal cell carcinoma. J. Cell Mol. Med. 15, 109-118
39. Beck, T., and Miller, B. G. (2013) Structural basis for regulation of human glucokinase by glucokinase regulatory protein. Biochemistry 52, 6232-6239